Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  10.60 0.65% 1,647.20 1,644.60 1,645.20 1,653.60 1,620.80 1,627.20 10,986,803 16:35:01
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.0 6,221.0 93.9 17.5 82,872

Arrowhead Pharma in License Agreement With GSK for ARO-HSD

22/11/2021 9:55pm

Dow Jones News

Glaxosmithkline (LSE:GSK)
Historical Stock Chart

From Nov 2021 to Jan 2022

Click Here for more Glaxosmithkline Charts.

By Stephen Nakrosis


Arrowhead Pharmaceuticals Inc. on Monday said it entered an exclusive license agreement with GlaxoSmithKline which will see GSK develop and commercialize Arrowhead's ARO-HSD.

Arrowhead said ARO-HSD is an "investigational RNA interference therapeutic in a Phase 1/2 trial that is currently being developed as a treatment for patients with nonalcoholic steatohepatitis."

Arrowhead will receive an upfront payment of $120 million. Arrowhead is also eligible for additional payments tied to future trials and regulatory approval, as well as for commercial milestone payments and royalties, according to the companies.

GlaxoSmithKline will receive an exclusive license to develop and commercialize ARO-HSD in all territories except Greater China, which will be retained by Arrowhead, the companies said.

The deal is expected to close in the first quarter of next year.


Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

November 22, 2021 16:40 ET (21:40 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Glaxosmithkline Chart

1 Year Glaxosmithkline Chart

1 Month Glaxosmithkline Chart

1 Month Glaxosmithkline Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220121 19:47:24